Effects of Empagliflozin on Metabolic Parameters in Polycystic Ovary Syndrome

A Randomized Controlled Study

Zeeshan Javed; Maria Papageorgiou; Harshal Deshmukh; Alan S. Rigby; Unaiza Qamar; Jehangir Abbas; Amer Y. Khan; Eric S. Kilpatrick; Stephen L. Atkin; Thozhukat Sathyapalan


Clin Endocrinol. 2019;90(6):805-813. 

In This Article


Empagliflozin treatment over a 12-week period had beneficial effects on weight, BMI, waist and hip circumference and total body fat in overweight and obese women with PCOS compared to metformin, but no differences were seen in hormonal and metabolic parameters including insulin resistance and androgen levels. Placebo-controlled and comparative treatment randomized controlled trials of longer-term duration are needed to confirm these findings and provide further insights into the effects of empagliflozin on PCOS-related outcomes in women with PCOS with different PCOS phenotypes and PCOS-related complications (eg with/without diabetes), before empagliflozin gains a therapeutic place in PCOS. Lifestyle interventions (preferably multicomponent including diet, exercise and behavioural strategies) should still be considered the first line of treatment for overweight/obese women with PCOS for reductions in body weight, central obesity and insulin resistance.[3]